The impact of early pregnancy metabolic disorders on pregnancy outcome and the specific mechanism

Table 2 Metabolism-related medications

Medication	Target	Study model	Effect	Refs
AZD3965	MCT-1	Male BALB/c, male DBA/2 and female CBA/J mice	Block lactic acid intake	[58]
Leptin	NO/cGMP/PK-G	Swiss albino mice	Inhibit uterine contractions	[87]
SGC707	PRMT3/ADMA/NO	Female CBA/J, male DBA/2 and male BALB/c mice	Inhibit the apoptosis of trophoblast cells	[96]
Vitamin D	CBS	Human blood samples Human placenta samples	Inhibit inflammatory immune response	[102]
Astaxanthin	Nrf2/HO-1	C57BL/KsJ db/ + mice	Inhibits oxidative stress in the body and enhances antioxidant enzyme activity	[118]
ALA DHLA	FAK/Src/HIF-1α	Human samples	stimulate Nrf2-dependent gene transcription and inhibit NF-kB activity	[120]

MCT-1 monocarboxylate transporter protein 1, PK-G protein kinase G, PRMT3 protein l-arginine methyltransferase 3, ADMA asymmetric dimethylarginine, CBS cystathionine beta-synthase, Nrf2 Nuclear factor-erythroid 2 related factor 2, HO-1 Heme Oxygenase-1, ALA alpha lipoic acid, DHLA dihydrolipoic acid, FAK focal adhesion kinase, Src steroid receptor coactivator, HIF-1α Hypoxia inducible factor 1 α

ISSN: 2047-783X